Human leukocyte antigen A2 (HLA-A2) on alpha-type-1 polarized dendritic cells (HLA-A2/alpha-DC1)

Human leukocyte antigen A2 (HLA-A2) is a major histocompatibility complex (MHC) class I molecule (UniProt P01892) that plays a pivotal role in the cellular immune response by presenting peptide antigens to CD8+ cytotoxic T lymphocytes (CTLs). When expressed on alpha-type-1 polarized dendritic cells (alpha-DC1), HLA-A2 acts as a highly efficient scaffold for the induction of potent anti-tumor immunity. Alpha-DC1 cells are a specialized subset of dendritic cells matured using a specific cytokine cocktail (typically including IL-1beta, TNF-alpha, IFN-alpha, IFN-gamma, and poly-I:C) to maximize their production of interleukin-12 (IL-12p70), which is essential for driving Th1-type immune responses (Lee et al., 2008, J Immunother). This target is central to the development of personalized cancer vaccines, where HLA-A2-positive patients receive alpha-DC1s loaded with tumor-associated antigens to trigger the targeted destruction of malignant cells. By combining high-density antigen presentation with strong Th1-polarizing signals, this therapeutic approach aims to overcome tumor-induced immunosuppression and achieve durable clinical responses in various malignancies, including melanoma and glioblastoma (Kalinski et al., 2015, Front Immunol).

Other names

HLA-A*02MHC class I antigen A*02Major histocompatibility complex, class I, Aalpha-DC1Type-1 polarized dendritic cells

HLA-A2 molecules on alpha-type-1 polarized dendritic cells present specific antigenic peptides to CD8+ T cells, while the alpha-DC1 phenotype provides high levels of IL-12p70 to drive Th1 polarization and cytotoxic T lymphocyte (CTL) activation.